Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO

This article was originally published in The Pink Sheet Daily

Executive Summary

The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.

You may also be interested in...



Deals Of The Week: How Do 2013 Biotech Deal Stats Stack Up After Amgen/Onyx?

A busy summer of biotech acquisitions, including the pricey buyouts of Onyx by Amgen and Elan by Perrigo, has lifted the number of U.S. public biotech acquisitions so far in 2013 – and increased the average value of those deals. In other deal news, Endo plans to acquire Boca Pharmacal, Medimmune will buy out Amplimmune, and Eli Lilly signed a diabetes research deal with Zealand Pharma.

Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices

Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.

Takeda, Sanofi Team Up To Explore DPP-4 Market In China

Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel